Rare disease

Hereditary angioedema with C1 esterase inhibitor deficiency

10 clinical trials

Quick filters

Clinical trials for Hereditary angioedema with C1 esterase inhibitor deficiency

10 trials across Europe

See all trials →

Quick filters

10 Clinical trials

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

Investigational

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:NAVENIBART
Sponsor:Astria Therapeutics Inc.

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

Registered drug

Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

Registered drug

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Registered drug

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Investigational

Study of Navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

Investigational

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:NAVENIBART
Sponsor:Astria Therapeutics Inc.

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

InvestigationalNo placebo

Study on the Safety and Effects of Sebetralstat for Children Aged 2-11 with Hereditary Angioedema Type I or II

InvestigationalNo placebo

France

Participants:0–17 years
Substances:Sebetralstat
Sponsor:Kalvista Pharmaceuticals Limited

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

InvestigationalNo placebo

Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:NAVENIBART
Sponsor:Astria Therapeutics Inc.

Contact Research Centre

See all trials →

Hereditary angioedema with C1 esterase inhibitor deficiency

Clinical trials for Hereditary angioedema with C1 esterase inhibitor deficiency

Hereditary angioedema with C1 esterase inhibitor deficiency+1

A study of navenibart for long-term safety in patients with hereditary angioedema

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

Hereditary angioedema with C1 esterase inhibitor deficiency

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Study of Navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

Hereditary angioedema with C1 esterase inhibitor deficiency

Study on the Safety and Effects of Sebetralstat for Children Aged 2-11 with Hereditary Angioedema Type I or II

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.